D. Boral Capital Reaffirms "Buy" Rating for Context Therapeutics (NASDAQ:CNTX)

D. Boral Capital reissued their buy rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a research report released on Tuesday,Benzinga reports. The firm currently has a $9.00 price target on the stock.

Other analysts have also recently issued reports about the stock. Citizens Jmp raised shares of Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Friday, March 21st. William Blair initiated coverage on Context Therapeutics in a research report on Monday, April 21st. They issued an "outperform" rating for the company. Finally, JMP Securities started coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $6.17.

Context Therapeutics Stock Up 0.8 %

CNTX traded up $0.01 during mid-day trading on Tuesday, reaching $0.87. 30,000 shares of the company traded hands, compared to its average volume of 300,208. The company's fifty day moving average price is $0.78 and its 200-day moving average price is $1.16. The stock has a market capitalization of $78.01 million, a P/E ratio of -0.96 and a beta of 2.18. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. As a group, sell-side analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in Context Therapeutics in the 4th quarter worth approximately $29,000. Citadel Advisors LLC purchased a new position in Context Therapeutics during the fourth quarter valued at $31,000. Shay Capital LLC purchased a new position in Context Therapeutics during the fourth quarter valued at $52,000. Clear Harbor Asset Management LLC lifted its stake in Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after purchasing an additional 21,804 shares in the last quarter. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Context Therapeutics during the 4th quarter valued at about $94,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.